Honeywell International R&D increased by 24.6% to $492.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.3%, from $416.00M to $492.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 7.6% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $333.25M | $333.25M | $333.25M | $350.00M | $386.00M | $387.00M | $355.00M | $357.00M | $375.00M | $364.00M | $279.00M | $360.00M | $382.00M | $368.00M | $344.00M | $416.00M | $481.00M | $497.00M | $395.00M | $492.00M |
| QoQ Change | — | +0.0% | +0.0% | +5.0% | +10.3% | +0.3% | -8.3% | +0.6% | +5.0% | -2.9% | -23.4% | +29.0% | +6.1% | -3.7% | -6.5% | +20.9% | +15.6% | +3.3% | -20.5% | +24.6% |
| YoY Change | — | — | — | — | +15.8% | +16.1% | +6.5% | +2.0% | -2.8% | -5.9% | -21.4% | +0.8% | +1.9% | +1.1% | +23.3% | +15.6% | +25.9% | +35.1% | +14.8% | +18.3% |